斯丹賽生物技術公司任命 Lucy Lu 博士為首席運營官
April 06, 2022 20:00 ET
|
Innovative Cellular Therapeutics
马里兰州罗克维尔, April 07, 2022 (GLOBE NEWSWIRE) -- 致力於開發以實體瘤為重點的嵌合抗原受體（CAR）T細胞治療綜合平台的臨床階段生物技術公司--斯丹賽生物技術（即：Innovative Cellular Therapeutics，簡稱“ICT”）今天宣佈，任命Lucy Lu 醫學博士為首席運營官。 ...
斯丹賽生物技術公司任命 Lucy Lu 博士為首席運營官
April 06, 2022 20:00 ET
|
Innovative Cellular Therapeutics
馬里蘭州羅克維爾, April 07, 2022 (GLOBE NEWSWIRE) -- 致力於開發以實體瘤為重點的嵌合抗原受體（CAR）T細胞治療綜合平台的臨床階段生物技術公司--斯丹賽生物技術（即：Innovative Cellular Therapeutics，簡稱“ICT”）今天宣佈，任命Lucy Lu 醫學博士為首席運營官。 ...
Innovative Cellular Therapeutics Appoints Robert Dallimore as SVP of Quality & Compliance
April 06, 2022 08:00 ET
|
Innovative Cellular Therapeutics
ROCKVILLE, Md., April 06, 2022 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor...
Innovative Cellular Therapeutics Appoints Lucy Lu as Chief Operations Officer
April 06, 2022 08:00 ET
|
Innovative Cellular Therapeutics
ROCKVILLE, Md., April 06, 2022 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor...
美國FDA批准斯丹賽生物基於通用CoupledCAR® 技術平台的首個候選產品GCC19CART 用於治療復發或難治轉移性結直腸癌的I期臨床試驗
September 01, 2021 20:00 ET
|
Innovative Cellular Therapeutics
ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) --...
美国FDA批准斯丹赛生物基于通用CoupledCAR® 技术平台的首个候选产品GCC19CART 用于治疗复发或难治转移性结直肠癌的I期临床试验
September 01, 2021 20:00 ET
|
Innovative Cellular Therapeutics
ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) --...
Innovative Cellular Therapeutics Receives FDA Clearance of IND Application to Initiate a Phase 1 Clinical Trial for GCC19CART, a CoupledCAR® Platform Product Candidate for Relapsed or Refractory Metastatic Colorectal Cancer
September 01, 2021 08:00 ET
|
Innovative Cellular Therapeutics
ROCKVILLE, Md., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a Maryland based clinical stage biotechnology company developing the CoupledCAR® platform of chimeric...
斯丹賽生物技術公司任命Eugene Kennedy為首席醫療官
March 17, 2021 21:46 ET
|
Innovative Cellular Therapeutics
馬里蘭州羅克維爾市, March 18, 2021 (GLOBE NEWSWIRE) -- 致力於開發以實體瘤為重點的嵌合抗原受體（CAR）T細胞治療綜合平台的臨床階段生物技術公司斯丹賽生物技術（即：Innovative Cellular Therapeutics，簡稱「ICT」）今天宣佈，任命Eugene (Gene)...
斯丹赛生物技术公司任命Eugene Kennedy为首席医疗官
March 17, 2021 21:46 ET
|
Innovative Cellular Therapeutics
马里兰州罗克维尔市, March 18, 2021 (GLOBE NEWSWIRE) -- 致力于开发以实体瘤为重点的嵌合抗原受体（CAR）T细胞治疗综合平台的临床阶段生物技术公司斯丹赛生物技术（即：Innovative Cellular Therapeutics，简称“ICT”）今天宣布，任命Eugene (Gene)...
Innovative Cellular Therapeutics Appoints Eugene Kennedy as Chief Medical Officer
March 16, 2021 08:00 ET
|
Innovative Cellular Therapeutics
ROCKVILLE, Md., March 16, 2021 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor...